Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy

Haifa Kathrin Al-Ali • 19 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Navtemadlin Ruxolitinib

Haifa Kathrin Al-Ali, MD, University Hospital of Halle, Halle, Germany, discusses KRT‑232, a murine double minute 2 inhibitor (MDM2I), for myelofibrosis relapsed or refractory (R/R) to Janus‑associated kinase (JAK) inhibitor treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Haifa Kathrin Al-Ali

2:57
Unmet needs in polycythemia vera: improving symptoms & qualify of life
Haifa Kathrin Al-Ali • 11 Jun 2023
1:34
Pelabresib in myelofibrosis: the MANIFEST trials
Haifa Kathrin Al-Ali • 11 Jun 2023
2:04
Phase I/II study of a novel BET inhibitor, BMS-986158, alone & with ruxolitinib or fedratinib in MF
Haifa Kathrin Al-Ali • 11 Jun 2023
1:14
The application of JAK inhibitors in the treatment of polycythemia vera and myelofibrosis
Haifa Kathrin Al-Ali • 9 Jun 2016

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals